BVXV - BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Developing Innovative Inhaled NanoAb Therapeutics for Multiple Indications Including COVID-19
- Current monoclonal antibody therapies less effective against emerging COVID-19 variants
- BiondVax is developing an inhaled nanosized antibody (NanoAb) therapy for COVID-19 with human clinical Phase 1/2a results anticipated in 2023
- The global monoclonal antibodies market was valued at $185.5 billion in 2021 and is projected to grow at a CAGR of 11.3% due to the rising prevalence of chronic diseases and demand for biologics
- The biologics market size was valued at $366.5 billion in 2021 and is expected to reach $719.94 billion by 2030
According to a new study, new COVID-19 subvariants have become dominant in recent months, rendering some current vaccines and treatments less effective, which could results in a surge of breakthrough infections. To date, the BQ.1, BQ.1.1, XBB, and XBB.1 omicron subvariants are the most immune evasive variants of COVID-19 – causing 72% of new infections in the United States, according to data from the Centers for Disease Control and Prevention (https://ibn.fm/0n3vY).
With scientists finding that these subvariants are “barely susceptible to neutralization” by vaccines, including the new omicron boosters, the immune response of people vaccinated and who had breakthrough...
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at http://ibn.fm/BVXV
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text "Biotech" to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.